Whole-body F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography imaging in the follow-up of metastatic uveal melanoma

Melanoma Research

Volumn 20, Issue 6, 2010, Pages 511-516

  Klingenstein, Annemarie ^a   Haug, Alexander R ^a   Nentwich, Martin M ^a   Tiling, Reinhold ^a   Schaller, Ulrich C ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

eye; metastases; positron emission tomography computed tomography scan; tumor; uveal melanoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IOPROMIDE;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRACHYTHERAPY; CANCER DIAGNOSIS; CHOROID MELANOMA; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; ECHOGRAPHY; ENUCLEATION; FEMALE; FOLLOW UP; HUMAN; IMAGING SYSTEM; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MELANOMA; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THORAX RADIOGRAPHY; UVEA TUMOR; X RAY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; UVEAL NEOPLASMS;

EID: 78349309235     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3283403d6c     Document Type: Article

References (27)

1. Hu DN, Yu GP, McCormick SA, Schneider S, Finger PT. Population-based incidence of uveal melanoma in various races and ethnic groups. Am J Ophthalmol 2005; 140:612-617.
2. Kivelä T, Eskelin S, Kujala E. Metastatic uveal melanoma. Int Ophthalmol Clin 2006; 46:133-149.
3. Schuster R, Bechrakis NE, Stroux A, Busse A, Schmittel A, Scheibenbogen C, et al. Circulating tumor cells as prognostic factor for distant metastases and survival in patients with primary uveal melanoma. Clin Cancer Res 2007; 13:1171-1178.
4. Gamel JW, McLean IW, McCurdy JB. Biologic distinctions between cure and time to death in 2892 patients with intraocular melanoma. Cancer 1993;119:786-791.
5. Peters S, Voelter V, Zografos L, Pampallona S, Peters S, Halkic N, et al. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol 2006; 17:578-583.
6. Schmittel A, Scheulen ME, Bechrakis NE, Strumberg D, Baumgart J, Bornfeld N, et al. Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma. Melanoma Res 2005; 15:205-207. (Pubitemid 40839469)
7. Schuster R, Lindner M, Wacker F, Krössin M, Bechrakis NE, Foerster MH, et al. Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome. Melanoma Res 2010; 20:191-196.
8. Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, et al. Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23. J Clin Oncol 2004; 22:2438-2444.
9. Antoch G, Saoudi N, Kuehl H, Dahmen G, Mueller SP, Beyer T, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 2004; 22:4357-4368.
10. Manning K, Tepfer B, Goldklang G, Loyd R, Garimella P, Halkar R. Clinical practice guidelines for the utilization of positron emission tomography/computed tomography imaging in selected oncologic applications: suggestions from a provider group. Mol Imag Biol 2007; 9:324-332.
11. Schöder H, Larson SM, Yeung HWD. PET/computed tomography in oncology: integration into clinical management of lymphoma, melanoma and gastrointestinal malignancies. J Nucl Med 2004; 45:72S-81S.
12. Haug AR, Schmidt GP, Klingenstein A, Heinemann V, Stieber P, Priebe M, et al. F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the follow-up of breast cancer with elevated levels of tumor markers. J Comput Assist Tomogr 2007; 31:629-634.
13. Freudenberg LS, Schueler AO, Beyer T, Antoch G, Kühl H, Bornfeld N, et al. Whole-body fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in staging of advanced uveal melanoma. Surv Ophthalmol 2004; 49:537-540.
14. Kurli M, Reddy S, Tena LB, Pavlick AC, Finger PT. Whole body positron emission tomography/computertomography staging of metastatic choroidal melanoma. Am J Ophthalmol 2005; 140:193-199.
15. Finger PT, Kurli M, Reddy S,Tena LB, Pavlick AC Whole body PET/CT for initial staging of choroidal melanoma. Br J Ophthalmol 2005; 89:1270-1274.
16. Francken AB, Fulham MJ, Millward MJ,Thompson JF. Detection of metastastic disease in patients with uveal melanoma using positron emission tomography. EJSO 2005; 32:780-784.
17. Singh AD, Rennie IG, Kivela T, Seregard S, Grossniklaus H. The Zimmerman-McLean-Foster hypothesis: 25 years later. Br J Ophthalmol 2004; 88:962-967.
18. Servois V, Mariani P, Malhaire C, Petras S, Piperno-Neumann S, Plancher C, et al. Preoperative staging of liver metastases from uveal melanoma by magnetic resonance imaging (MRI) and fluorodeoxyglucose-positron emission tomography (FDG-PET). Eur J Surg Oncol 2010; 36:189-194.
19. Beyer T, Pietrzyk U, Knoess C, Vollmar S, Wienhard K, Kracht L. Multi-modality imaging of uveal melanomas using combined PET/CT, high-resolution PETand MR imaging. Nuklearmedizin 2008; 47:73-79.
20. Finger PT, Ainbinder D, Albert DM, Armitage JO, Augsburger JJ, Bechrakis NE, et al. Malignant melanoma of the uvea. In: Edge SB Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A III, editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010. pp. 550.
21. Klingenstein A, Haug AR, Nentwich MM, Messmer EM, Schaller UC. Hepatic metastases in CUP (cancer of unknown primary) and painful amaurosis. Ophthalmologe2010. doi: 10.1007/s00347-010-2131-x. [Epub ahead of print]
22. Finger PT, Chin KJ. [(18)F]Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) physiologic imaging of choroidal melanoma: before and after ophthalmic plaque radiation therapy. Int J Radiat Oncol Biol Phys 2010. doi:10.1016/j.ijrobp.2009.10.041 [Epub ahead of print]
23. 18F-FDG PET/CT imaging for N-and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol 2006; 24:1178-1187.
24. Townsend DW, Beyer T, Blodgett TM. PET/CT scanners: a hardware approach to image fusion. Semin Nucl Med 2003; 33:193-204.
25. Antoch G, Vogt FM, Bockisch A, Ruehm SG. Whole-body tumor staging: MRI or FDG-PET/CT? Radiologe 2004; 44:882-888.
26. Schaller UC, Bosserhoff AK, Neubauer AS, Buettner R, Kampik A, Mueller AJ. Melanoma inhibitory activity: a novel serum marker for uveal melanoma. Melanoma Res 2002; 12:593-599.
27. Haritoglou I, Wolf A, Maier T, Haritoglou C, Hein R, Schaller UC. Osteopontin and 'melanoma Inhibitory activity': comparison of two serological tumor markers in metastatic uveal melanoma patients. Ophthalmologica 2009; 223:239-243.